Full-Time

Clinical Specialist

Calyxo

Calyxo

201-500 employees

Develops and markets kidney stone devices

Compensation Overview

$80k - $120k/yr

+ Annual Variable Bonus + Auto Allowance + Cell Phone/Internet Allowance + Stock Options

New York, NY, USA

Remote

Willing to travel outside designated territory; ideal candidates reside in Long Island, NY.

Category
Biology & Biotech (2)
,
Requirements
  • Clinical experience such as scrub technician, X-Ray Technician, registered nurse or Bachelor of Science in Nursing, or Laser Technician.
  • Industry experience (1-3 years) for Clinical Specialist II.
  • Prior employment as a Clinical Specialist with a medical device company or experience working with Mobile Lithography Provider Companies (Litho provider) for Clinical Specialist II.
  • Comfortable with the pace required to be successful in a start-up for Clinical Specialist II.
  • Ability to provide intraoperative procedural guidance for Clinical Specialist II.
  • Willingness to travel outside of the designated territory for Clinical Specialist II.
  • Industry experience: 3+ years of full-time employment by a medical device company as a Clinical Specialist focused on case coverage and patient outcomes for Sr. Clinical Specialist.
  • Clinical experience: Intraoperative Coaching Experience for Sr. Clinical Specialist.
  • Operating Room experience: Fluent in Staff and Support Training for Sr. Clinical Specialist.
  • Track record of success; Urology experience preferred for Sr. Clinical Specialist.
  • Under Sr. Clinical Specialist: Understands the medical device industry; Comfortable with the pace required to be successful in a start-up; Ability to provide intraoperative procedural guidance; Understands sales processes and training; Willingness to travel outside the designated territory.
  • General Requirements: Experience in surgical technique and sterile procedures in the operating room.
  • General Requirements: Experience utilizing fluoroscopy is a plus.
  • General Requirements: Customer relationship and procedural skill development are highly desired.
  • General Requirements: Degree or certification in a medical-related field (for example LPN, RN, Surg Tech, Rad Tech, etc) is highly desirable.
  • General Requirements: Able to travel by car up to 90%.
  • General Requirements: Compliance with relevant county, state, and federal rules regarding vaccinations.
Responsibilities
  • Provide clinical case coverage as assigned
  • Train the surgical team to assist in good patient outcomes and verbally support cases during training period
  • Acquire and maintain current knowledge of perioperative surgical technology practice and hospital policies and procedures
  • Develop technical acumen to a level to serve as an educational resource
  • Demonstrate appropriate interactions with all hospital service providers
  • Maintain and prepare equipment and kits for surgery, including Quality Control audits of equipment and kits
  • Troubleshoot equipment according to standard procedure
  • Provide intra-operative clinical product support
  • Ensure that 100% of received inventory and returned inventory matches shipping documents
  • Reconcile inventory/usage as well as missing inventory
  • Assist in the delivery of procedural training to physicians and medical staff
  • Be an effective member of the commercial team and play a key role in ensuring positive clinical outcomes
  • In partnership with TSM, perform account management: such as Account Set Up, Clinical Engagement, Case Support and Clinical Outcomes
  • In Partnership with TSM, support education of APPs, Office and Hospital Staff
  • In partnership with TSM, help facilitate and support Residency Education
  • Ensure compliance with all company policies, including the quality policy, on label promotion and interactions with health care professionals
  • Collaborate with Clinical Specialist teams to review and discuss case presentations and peer to peer knowledge sharing
  • Other duties as assigned
Desired Qualifications
  • Urology experience preferred.
  • Degree or certification in a medical-related field (for example LPN, RN, Surg Tech, Rad Tech, etc) is highly desirable

Calyxo, Inc. develops medical devices for kidney stone treatment. Its products are designed for use by urologists in hospitals and clinics to treat kidney stones more effectively, prioritizing patient safety and efficient procedures. The company works closely with leading U.S. urologists to translate clinical needs into devices, focusing on making treatments safer and easier for clinicians. Unlike some competitors, Calyxo emphasizes clinician collaboration and proven clinical relevance in its device development, backed by leadership with startup and product-launch experience. The goal is to improve patient care by delivering advanced devices that help urologists achieve better clinical outcomes and expand the devices’ reach through commercialization to healthcare providers.

Company Size

201-500

Company Stage

Series F

Total Funding

$137.2M

Headquarters

Pleasanton, California

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • Series F raised $40M led by Ally Bridge Group and Janus Henderson Investors.
  • CVAC system treated over 40,000 patients, advancing toward standard of care.
  • ASPIRE study at AUA showed superior clearance independent of stone burden in 101 patients.

What critics are saying

  • Boston Scientific's LithoClast Trilogy erodes market share via hospital contracts in 12-24 months.
  • Cook Medical's NGage basket undercuts CVAC pricing by 30% in 12-18 months.
  • FDA Class I recall triggers withdrawal due to 5% ureteral perforation risks in 3-9 months.

What makes Calyxo unique

  • CVAC System integrates ureteroscopy, laser lithotripsy, irrigation, and aspiration in one device.
  • SURE procedure with CVAC achieves 97% volumetric stone clearance versus standard URS.
  • Redesigned CVAC received FDA clearance in March 2024 for minimally invasive treatment.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Calyxo who can refer or advise you

Benefits

Health Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Stock Options

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

2%

2 year growth

8%
StreetInsider
Apr 14th, 2026
Calyxo raises $40M Series F as CVAC kidney stone system treats 40,000 patients

Calyxo, a medical device company focused on kidney stone treatment, has closed a $40 million Series F financing round led by Ally Bridge Group and Janus Henderson Investors. Questa Capital, Avidity Partners and CRG also participated. The funding follows a milestone of 40,000 patients treated with Calyxo's CVAC System, an aspiration-based stone removal device. The system uses irrigation and vacuum aspiration to continuously clear stone fragments during procedures, enabling more complete stone clearance. Proceeds will support commercial expansion, clinical evidence generation through ongoing studies evaluating long-term outcomes, and continued innovation in kidney stone care. The CVAC System received FDA clearance in 2024 and is positioned as an all-in-one solution for minimally invasive kidney stone removal.

Business Wire
May 14th, 2024
Study Presented At Aua Shows Superior Kidney Stone Clearance Rates For Sure Procedure Using Calyxo’S Cvac System Vs Standard Urs

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company developing innovative solutions for patients with kidney stones, has announced that positive study results for its CVAC System were presented last week at the American Urological Association (AUA) Annual Meeting in San Antonio. The CVAC System, a revolutionary technology that is designed for complete kidney stone removal, was the focus of the prospective, randomized, multi-center ASPIRE study, which compared the safety and efficacy of steerable ureteroscopic renal evacuation (SURE) vs ureteroscopy (URS) with basketing. The 30-day results of the ASPIRE study were presented at the AUA Meeting by urologist Thomas Chi, MD of the University of California, San Francisco. In 101 patients, SURE demonstrated statistically superior stone clearance and significantly lower residual stone volume compared to standard URS. Unlike standard URS, the CVAC System achieved these results independent of baseline stone burden. Safety was comparable between groups

Business Wire
Mar 26th, 2024
Calyxo Announces Fda Clearance For New, Redesigned Cvac System

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company developing innovative solutions for patients with kidney stones, announced that it has received FDA clearance for its new, redesigned CVAC System, which enables a minimally invasive approach to kidney stone treatment. More than 50 procedures have already been completed by 12 urologists with the new CVAC System, yielding strong patient outcomes and consistently positive physician feedback. Clinical studies have shown that residual stone fragments are associated with a 20%-44% incidence of post-procedure problems, including pain, infection, emergency department visits, hospitalization and need for retreatment. Steerable ureteroscopic renal evacuation (SURE) using the original CVAC Aspiration System has been used to successfully treat more than 1,500 patients in the U.S., demonstrating that vacuum aspiration of stone fragments improves clinical outcomes, with 97% volumetric stone clearance and a high likelihood of avoiding the need for a secondary or more invasive procedure (according to clinical study data collected in patients treated with the device)

FinSMEs
Dec 12th, 2023
Calyxo Raises $50M in Series D Funding

Calyxo, a Pleasanton, CA-based medical device company developing next-generation treatment solutions for patients with kidney stones, raised $50M in Series D funding.

Questa Capital
Jul 6th, 2022
Questa Capital invests into Calyxoinc in $32.7M

Calyxo, Inc., a medical device company focused on improving care for patients with kidney stones by delivering next generation treatment solutions, has announced the closing of a $32.7 million Series C financing round led by Questa Capital and CRG.